Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
147
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

253
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
253
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human rights-based mental healthcare: new developments, introducing a themed series of papers.

BJPsych open·2026
Same author

Return of results is important to heterogeneous research participants: A single-site survey.

Journal of clinical and translational science·2026
Same author

Jailing People With Mental Illness While Awaiting Commitment Hearings.

Psychiatric services (Washington, D.C.)·2026
Same author

Imputing Parental Genotypes Through Mendelian Imputation: Ethical and Legal Considerations.

Behavior genetics·2026
Same author

Serious Mental Illness, Dependence, and Care: California's Legal Initiatives on Grave Disability.

Psychiatric services (Washington, D.C.)·2025
Same author

"Self-Induced Symptoms" and the Insanity Defense.

Psychiatric services (Washington, D.C.)·2025

Related Experiment Video

Updated: Jun 7, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.0K

Electroconvulsive Therapy, Manufacturers' Liability, and Learned Intermediaries.

Paul S Appelbaum1

  • 1Department of Psychiatry, Columbia University, New York City.

Psychiatric Services (Washington, D.C.)
|November 19, 2024
PubMed
Summary

The learned intermediary rule protects drug and device makers from direct patient warnings. A California court now makes it easier for patients to seek compensation for undisclosed risks, like memory loss from electroconvulsive therapy.

Keywords:
CompensationElectroconvulsive therapy (ECT)Law and psychiatryLearned intermediary ruleMedical harm

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.3K

Related Experiment Videos

Last Updated: Jun 7, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.0K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.3K

Area of Science:

  • Medical Law
  • Product Liability
  • Neurology

Background:

  • The learned intermediary rule shields pharmaceutical and medical device manufacturers from direct patient disclosure requirements.
  • Manufacturers are obligated to warn prescribing physicians of potential risks associated with their products.
  • Determining patient compensation for harm due to undisclosed risks presents legal challenges.

Purpose of the Study:

  • To analyze the California Supreme Court's ruling on the learned intermediary rule in a case involving electroconvulsive therapy (ECT).
  • To examine how the court's decision impacts a patient's ability to recover damages for injuries caused by a lack of risk disclosure.

Main Methods:

  • Legal case analysis focusing on the California Supreme Court's decision.
  • Examination of the legal standards for demonstrating causation between a lack of warning and patient harm.

Main Results:

  • The court broadened the criteria for plaintiffs to prove that the absence of a warning directly caused their injury.
  • This expansion simplifies the process for patients seeking compensation for harm resulting from undisclosed risks.

Conclusions:

  • The California Supreme Court's ruling potentially enhances patient recourse against manufacturers for failure to disclose known risks.
  • The decision may lead to increased accountability for drug and device manufacturers regarding risk communication.